ARTICLE II -- REPRESENTATIONS AND WARRANTIES OF THE COMPANYStock Purchase Agreement • May 17th, 1999 • Repligen Corp • Biological products, (no disgnostic substances) • Massachusetts
REPLIGEN CORPORATION By: ------------------------------------------ Walter C. Herlihy President and CEO Address: 117 Fourth Avenue Needham, MA 02194 Attention: Secretary PURCHASE FORM The undersigned, _____________________ hereby irrevocably elects to...Warrant Agreement • June 26th, 1998 • Repligen Corp • Biological products, (no disgnostic substances) • Delaware
WHEREVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS ARE DENOTED BY AN ASTERISK), SUCH CONFIDENTIAL INFORMATION HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT...License Agreement • November 14th, 2000 • Repligen Corp • Biological products, (no disgnostic substances) • Michigan
Exhibit 4.1 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD OR TRANSFERRED UNLESS SUCH SALE OR TRANSFER IS IN ACCORDANCE WITH THE REGISTRATION REQUIREMENTS...Common Stock Purchase Warrant • August 12th, 2003 • Repligen Corp • Biological products, (no disgnostic substances) • Massachusetts
REPLIGEN CORPORATION, Issuer AND WILMINGTON TRUST, NATIONAL ASSOCIATION, Trustee INDENTURE Dated as of July 19, 2019 Senior Debt SecuritiesIndenture • July 22nd, 2019 • Repligen Corp • Biological products, (no disgnostic substances) • New York
INDENTURE, dated as of July 19, 2019, among REPLIGEN CORPORATION, a Delaware corporation (the “Company”), and WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association as trustee (the “Trustee”):
EXHIBIT 10.1 SUPPLY AGREEMENT This agreement ("Agreement") is made as of May 26, 1999, by and between Repligen Corporation ("REPLIGEN"), a Delaware corporation with principal offices at 117 Fourth Ave., Needham, MA 02494 and Amersham Pharmacia Biotech...Supply Agreement • August 13th, 1999 • Repligen Corp • Biological products, (no disgnostic substances) • New York
ARTICLE IStock Purchase Agreement • May 2nd, 2003 • Repligen Corp • Biological products, (no disgnostic substances) • New York
REPLIGEN CORPORATION AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of December 14, 2023 1.00% Convertible Senior Notes due 2028Indenture • December 15th, 2023 • Repligen Corp • Biological products, (no disgnostic substances) • New York
INDENTURE, dated as of December 14, 2023, between REPLIGEN CORPORATION, a Delaware corporation, as issuer (the “Company”, as more fully set forth in Section 1.01) and WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee”, as more fully set forth in Section 1.01).
EXHIBIT 10.1 WHEREVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS ARE DENOTED BY AN ASTERISK), SUCH CONFIDENTIAL INFORMATION HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL...Licensing Agreement • February 14th, 2000 • Repligen Corp • Biological products, (no disgnostic substances)
ARTICLE II -- REPRESENTATIONS AND WARRANTIES OF THE COMPANYStock Purchase Agreement • March 21st, 2000 • Repligen Corp • Biological products, (no disgnostic substances) • Massachusetts
LEASE BETWEENLease Agreement • February 14th, 2002 • Repligen Corp • Biological products, (no disgnostic substances)
andRights Agreement • March 4th, 2003 • Repligen Corp • Biological products, (no disgnostic substances) • Delaware
Repligen Corporation 117 Fourth Avenue Needham, MA 02494Financial Advisory Agreement • May 4th, 2000 • Repligen Corp • Biological products, (no disgnostic substances)
FORM INDEMNIFICATION AGREEMENTIndemnification Agreement • May 12th, 2016 • Repligen Corp • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of by and between Repligen Corporation, a Delaware corporation (the “Company”), and (“Indemnitee”).
ARTICLE II -- REPRESENTATIONS AND WARRANTIES OF THE COMPANYStock and Warrant Purchase Agreement • February 12th, 1998 • Repligen Corp • Biological products, (no disgnostic substances) • Massachusetts
Exhibit 4.1 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD OR TRANSFERRED UNLESS SUCH SALE OR TRANSFER IS IN ACCORDANCE WITH THE REGISTRATION REQUIREMENTS...Common Stock Purchase Warrant • November 14th, 2000 • Repligen Corp • Biological products, (no disgnostic substances) • Massachusetts
Exhibit 4.1 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this "Agreement") is made this 30th day of April 1999 by and among Repligen Corporation, a Delaware corporation (the "Company"), and the investors named in the attached SCHEDULE I...Stock Purchase Agreement • May 17th, 1999 • Repligen Corp • Biological products, (no disgnostic substances) • Massachusetts
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 2nd, 2015 • Repligen Corp • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (the “Agreement”) is made this 26th day of February, 2015 between Repligen Corporation, a Delaware corporation (the “Company”), and Anthony Hunt (the “Executive”) and shall become effective on the date of the Company’s 2015 annual stockholder meeting (the “Effective Date”) except for Section 2(c)(i) which shall be effective as of the date hereof.
REPLIGEN CORPORATION AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of July 19, 2019 to Indenture for Senior Debt Securities Dated as of July 19, 2019 0.375% Convertible Senior Notes due 2024First Supplemental Indenture • July 22nd, 2019 • Repligen Corp • Biological products, (no disgnostic substances) • New York
FIRST SUPPLEMENTAL INDENTURE dated as of July 19, 2019 (this “Supplemental Indenture”), between REPLIGEN CORPORATION, a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01), supplementing the Indenture for Senior Debt Securities dated as of July 19, 2019, between the Company and the Trustee (the “Base Indenture” and the Base Indenture, as amended and supplemented by this Supplemental Indenture, and as it may be further amended or supplemented from time to time with respect to the Notes, the “Indenture”).
EXHIBIT 2.1 WHEREVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS ARE DENOTED BY AN ASTERISK), SUCH CONFIDENTIAL INFORMATION HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL...Patent Purchase Agreement • March 24th, 1999 • Repligen Corp • Biological products, (no disgnostic substances) • Massachusetts
ContractUnderwriting Agreement • July 18th, 2019 • Repligen Corp • Biological products, (no disgnostic substances) • New York
Repligen Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representative (the “Representative”) an aggregate principal amount, as set forth on a term sheet substantially in the form of Schedule III hereto (the “Pricing Term Sheet”), of its 0.375% Convertible Senior Notes due 2024 (the “Firm Securities”). The Company also proposes to sell to the several Underwriters, at the option of the Underwriters, up to an additional principal amount as set forth the Pricing Term Sheet, of its 0.375% Convertible Senior Notes due 2024 (the “Option Securities”). The Firm Securities and the Option Securities are hereinafter referred to collectively as the “Securities”. The Securities will be convertible into cash, shares of common stock of the Company, par value $0.01 per share (the “Common Stock”), or a combination of cash and shares of Common Stock (any shares of Commo
June 10, 2014 Jon Snodgres Montville, NJ 07045 Re: Employment Agreement Dear Jon:Employment Agreement • July 15th, 2014 • Repligen Corp • Biological products, (no disgnostic substances) • Massachusetts
This letter agreement (the “Agreement”) sets forth the terms of your employment with Repligen Corporation (the “Company”). This Agreement supersedes any prior oral or written agreements or understandings related to the terms and conditions of your employment.
EXHIBIT 2.3 COLLATERAL ASSIGNMENT OF PATENTS THIS COLLATERAL ASSIGNMENT OF PATENTS (hereinafter referred to as the "Agreement"), dated as of March 9, 1999, by and between Repligen Corporation, a Delaware corporation (hereinafter referred to as the...Collateral Assignment of Patents • March 24th, 1999 • Repligen Corp • Biological products, (no disgnostic substances) • Massachusetts
ContractAsset Transfer Agreement • October 28th, 2011 • Repligen Corp • Biological products, (no disgnostic substances)
This Asset and Transfer Agreement (the “Agreement”) contains warranties that Novozymes Biopharma DK A/S (the “Seller”) and Novozymes Biopharma Sweden AB (the “Company”), on one hand, and Goldcup 7136 AB under name change to Repligen Sweden AB (the “Buyer”) and Repligen Corporation (the “Parent”), on the other hand, made to each other. These warranties were made only for the purposes of the Agreement and solely for the benefit of the Seller, the Company, the Buyer and the Parent as of specific dates, may be subject to important limitations and qualifications agreed to by the parties thereto and included in a confidential disclosure letter provided by the Seller and the Company to the Buyer and the Parent in connection with the signing of the Agreement, and may not be complete. Furthermore, these warranties may have been made for the purposes of allocating contractual risk between the Seller, the Company, the Buyer and the Parent instead of establishing these matters as facts, and may or
FOURTH AMENDMENTLease • May 9th, 2014 • Repligen Corp • Biological products, (no disgnostic substances)
THIS FOURTH AMENDMENT TO LEASE (the “Amendment”) is made and entered into as of the date of final execution (“Effective Date”), by and between CENTERPOINT ACQUISITIONS LLC, a Delaware limited liability company (“Landlord”), and REPLIGEN CORPORATION, a Delaware corporation (“Tenant”).
THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • June 1st, 2022 • Repligen Corp • Biological products, (no disgnostic substances) • Massachusetts
This Third Amended and Restated Employment Agreement (the “Agreement”) is made this 26th day of May 2022 between Repligen Corporation, a Delaware corporation (the “Company”), and Anthony Hunt (the “Executive”) and shall become effective on May 26, 2022 (the “Effective Date”).
EXHIBIT 10.2 CONSULTING AGREEMENT This Consulting Agreement is made as of November 1, 1981, between Repligen Corporation (the "Company"), a Delaware corporation having its principal place of business at 50 Staniford Street, Boston, Massachusetts 02114...Consulting Agreement • May 24th, 2002 • Repligen Corp • Biological products, (no disgnostic substances) • Massachusetts
LEASE BETWEEN REPLIGEN CORPORATION, AS TENANT AND WEST SEYON LLC, AS LANDLORD 35 SEYON STREET, WALTHAM, MASSACHUSETTSLease Agreement • February 26th, 2020 • Repligen Corp • Biological products, (no disgnostic substances) • Massachusetts
THIS LEASE is dated as of October 10, 2001, between the Landlord and the Tenant named below, and is of space in the Building described below.
REGENTS/REPLIGEN SETTLEMENT AGREEMENTSettlement Agreement • February 9th, 2005 • Repligen Corp • Biological products, (no disgnostic substances) • California
THIS REGENTS/REPLIGEN SETTLEMENT AGREEMENT (the “Agreement”) is made this 16th day of November 2004 by and among Repligen Corporation, a Delaware corporation (“Repligen”), The Regents of the University of California (the “Regents”) and Robert Naviaux, M.D., Ph.D. (“Naviaux”). Each of Repligen, the Regents and Naviaux is referred to herein as a “Party” and they are collectively referred to herein as the “Parties.”
WHENEVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS ARE DENOTED BY AN ASTERISK*), SUCH CONFIDENTIAL INFORMATION HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT....Settlement Agreement • August 5th, 2005 • Repligen Corp • Biological products, (no disgnostic substances) • Massachusetts
This agreement (this “Settlement Agreement”) and the other Settlement Documents referred to below are intended to contain all of the material terms of the agreement between Repligen Corporation (“Repligen”) and ChiRhoClin, Inc. (“CRC”) (collectively, the “Parties”), in settlement of the arbitration entitled Repligen Corporation v. ChiRhoClin, Inc., AAA No. 13 Y 00918 04 (the “Arbitration”).
2,734,375 Shares Repligen Corporation UNDERWRITING AGREEMENTUnderwriting Agreement • May 1st, 2019 • Repligen Corp • Biological products, (no disgnostic substances) • New York
Repligen Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A hereto (the “Underwriters”) an aggregate of 2,734,375 shares of its common stock, par value $0.01 per share (the “Common Stock”). The 2,734,375 shares of Common Stock to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 410,156 shares of Common Stock as provided in Section 2. The additional 410,156 shares of Common Stock to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” J.P. Morgan Securities LLC (“J.P. Morgan”) and Stephens Inc. have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sa
EXHIBIT 4.1 FORM OF STOCK PURCHASE WARRANT THIS WARRANT AND THE SHARES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD,...Stock Purchase Warrant • February 12th, 1998 • Repligen Corp • Biological products, (no disgnostic substances) • Delaware
ARTICLE I DEFINITIONSPatent Purchase Agreement • June 15th, 1999 • Repligen Corp • Biological products, (no disgnostic substances) • Massachusetts
SETTLEMENT AND RELEASE AGREEMENTSettlement Agreement • August 8th, 2008 • Repligen Corp • Biological products, (no disgnostic substances) • Delaware
THIS SETTLEMENT AND RELEASE AGREEMENT (the “Agreement”) is made and entered into as of April 7, 2008 (the “Effective Date”) by and between Repligen Corporation, a Delaware corporation having offices at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453, The Regents of the University of Michigan having offices at 1214 S. University Ave., 2nd Floor, Ann Arbor, MI 48104 and Bristol-Myers Squibb Company, a Delaware corporation having offices at Route 206 & Province Line Road, Princeton, NJ 08543.
REPLIGEN CORPORATION Incentive Stock Option AgreementIncentive Stock Option Agreement • June 14th, 2005 • Repligen Corp • Biological products, (no disgnostic substances) • Delaware
Repligen Corporation, a Delaware corporation (the “Company”), hereby grants as of the day of to (the “Employee”), an option to purchase a maximum of shares (the “Option Shares”) of its Common Stock, par value $.01 per share (“Common Stock”), at the price of $ per share, on the following terms and conditions:
